1. Radioembolization for hepatocellular carcinoma
Bruno Sangro, Mercedes Iñarrairaegui, Jose I. Bilbao 
Journal of Hepatology 
Volume 56, Issue 2, Pages (February 2012)
DOI: /j.jhep
Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

2. Fig. 1
Liver volume exposed to radiation is defined by the arteries into which radioactive microspheres are injected.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

3. Fig. 2
(Chemo)embolization and radioembolization. Upper panel: small (35μm) isotope-loaded particles are delivered into the smallest intratumoral blood vessels with the aim of delivering short-range irradiation in radioembolization. Medium (100–500μm) drug-eluting or simple particles are delivered into the medium-size vessels that irrigate tumor nodules with the aim of producing ischemia and eventually expose tumor cells to high concentrations of cytotoxic agents in (chemo)embolization. Lower panel: size comparison between microspheres used for arterial (chemo)embolization and radioembolization.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

4. Fig. 3
99mTc-MAA scan of a patient with a large tumor involving the right lobe treated in a lobar fashion. (A) A planar image from where lung shunting is calculated; (B) a SPECT image that reveal an intense uptake by the tumor (high tumor to non-tumor ratio); (C) an MR image of the tumor at baseline; and (D) an MR image of the tumor 2years later showing an intense partial response after 3 sessions of radioembolization.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

5. Fig. 4
Comparison between median overall survival observed in comparable subgroups of patients treated by radioembolization and sorafenib. Data for 299 sorafenib-treated patients was obtained from subanalysis of the SHARP trial. Data for 189 radioembolization-treated patients was obtained from subanalysis of a cohort of patients fulfilling the same inclusion criteria, namely Child-Pugh class A and either BCLC stage C or BCLC stage B with prior TACE or bulky disease (bilobar or >5 nodules) [33,47,49–52].
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

6. Fig. 5
Median overall survival of HCC patients treated with radioembolization, TACE, and sorafenib according to BCLC stage.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

7. Journal of Hepatology 2012 56, 464-473DOI: (10. 1016/j. jhep. 2011. 07
Copyright © 2011 European Association for the Study of the Liver Terms and Conditions